XTX Topco Ltd Buys New Shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

XTX Topco Ltd purchased a new position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 15,329 shares of the company’s stock, valued at approximately $100,000.

Several other large investors have also added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in shares of Larimar Therapeutics by 80.1% during the third quarter. Jane Street Group LLC now owns 113,783 shares of the company’s stock worth $745,000 after purchasing an additional 50,622 shares during the period. Wellington Management Group LLP lifted its stake in Larimar Therapeutics by 152.5% during the 3rd quarter. Wellington Management Group LLP now owns 105,246 shares of the company’s stock valued at $689,000 after acquiring an additional 63,563 shares during the period. Sphera Funds Management LTD. boosted its holdings in shares of Larimar Therapeutics by 32.6% in the 3rd quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company’s stock valued at $2,715,000 after acquiring an additional 102,009 shares during the last quarter. Quarry LP increased its stake in shares of Larimar Therapeutics by 50.0% in the third quarter. Quarry LP now owns 12,000 shares of the company’s stock worth $79,000 after acquiring an additional 4,000 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Larimar Therapeutics by 27.2% during the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after purchasing an additional 1,189,467 shares during the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LRMR shares. Wedbush began coverage on shares of Larimar Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Larimar Therapeutics in a report on Monday, December 16th. Robert W. Baird assumed coverage on Larimar Therapeutics in a report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 19th. Finally, Oppenheimer initiated coverage on shares of Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 target price for the company. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $20.43.

Larimar Therapeutics Stock Performance

Shares of NASDAQ LRMR opened at $4.01 on Friday. The firm has a fifty day moving average of $6.91 and a 200 day moving average of $7.62. The firm has a market cap of $255.87 million, a PE ratio of -3.49 and a beta of 0.86. Larimar Therapeutics, Inc. has a one year low of $3.01 and a one year high of $13.68.

Larimar Therapeutics (NASDAQ:LRMR) last released its earnings results on Wednesday, October 30th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same quarter in the previous year, the firm posted ($0.21) EPS. On average, equities analysts predict that Larimar Therapeutics, Inc. will post -1.16 EPS for the current fiscal year.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.